168 related articles for article (PubMed ID: 22074316)
1. Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice.
Bumbaca D; Xiang H; Boswell CA; Port RE; Stainton SL; Mundo EE; Ulufatu S; Bagri A; Theil FP; Fielder PJ; Khawli LA; Shen BQ
Br J Pharmacol; 2012 May; 166(1):368-77. PubMed ID: 22074316
[TBL] [Abstract][Full Text] [Related]
2. Optimal Saturated Neuropilin-1 Expression in Normal Tissue Maximizes Tumor Exposure to Anti-Neuropilin-1 Monoclonal Antibody.
Ma C; Dou X; Yan J; Wang S; Yang R; Su F; Zhang H; Su X
Anticancer Agents Med Chem; 2019; 19(18):2269-2275. PubMed ID: 31692439
[TBL] [Abstract][Full Text] [Related]
3. Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans.
Xin Y; Bai S; Damico-Beyer LA; Jin D; Liang WC; Wu Y; Theil FP; Joshi A; Lu Y; Lowe J; Maia M; Brachmann RK; Xiang H
Pharm Res; 2012 Sep; 29(9):2512-21. PubMed ID: 22707361
[TBL] [Abstract][Full Text] [Related]
4. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.
Pastuskovas CV; Mundo EE; Williams SP; Nayak TK; Ho J; Ulufatu S; Clark S; Ross S; Cheng E; Parsons-Reponte K; Cain G; Van Hoy M; Majidy N; Bheddah S; dela Cruz Chuh J; Kozak KR; Lewin-Koh N; Nauka P; Bumbaca D; Sliwkowski M; Tibbitts J; Theil FP; Fielder PJ; Khawli LA; Boswell CA
Mol Cancer Ther; 2012 Mar; 11(3):752-62. PubMed ID: 22222630
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors.
Xin Y; Li J; Wu J; Kinard R; Weekes CD; Patnaik A; Lorusso P; Brachmann R; Tong RK; Yan Y; Watts R; Bai S; Hegde PS
Clin Cancer Res; 2012 Nov; 18(21):6040-8. PubMed ID: 22962439
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model.
Xin Y; Xiang H; Jin D; Theil FP; Joshi A; Damico-Beyer LA; Bai S
J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):217-26. PubMed ID: 22382554
[TBL] [Abstract][Full Text] [Related]
7. A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
Patnaik A; LoRusso PM; Messersmith WA; Papadopoulos KP; Gore L; Beeram M; Ramakrishnan V; Kim AH; Beyer JC; Mason Shih L; Darbonne WC; Xin Y; Yu R; Xiang H; Brachmann RK; Weekes CD
Cancer Chemother Pharmacol; 2014 May; 73(5):951-60. PubMed ID: 24633809
[TBL] [Abstract][Full Text] [Related]
8. SPECT imaging of neuropilin receptor type-1 expression with 131I-labeled monoclonal antibody.
Dou X; Yan J; Zhang Y; Liu P; Jiang Y; Lv S; Zeng F; Chen X; Wang S; Zhang H; Wu H; Zhang H; Ouyang L; Su X
Int J Oncol; 2016 Sep; 49(3):961-70. PubMed ID: 27315007
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.
Weekes CD; Beeram M; Tolcher AW; Papadopoulos KP; Gore L; Hegde P; Xin Y; Yu R; Shih LM; Xiang H; Brachmann RK; Patnaik A
Invest New Drugs; 2014 Aug; 32(4):653-60. PubMed ID: 24604265
[TBL] [Abstract][Full Text] [Related]
10. 125I-labelling of an internally 75Se-labelled monoclonal antibody--biodistribution in tumour-bearing nude mice.
Grétarsdóttir J; Forssell Aronsson E; Jacobsson L; Hafsteinsdóttir O; Holmberg S; Hafström L; Lindegren S; Karlsson B; Lindholm L; Mattsson S
Nucl Med Biol; 1994 Nov; 21(8):1017-21. PubMed ID: 9234359
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution of monoclonal antibody Po66 in a human lung tumour-bearing mouse model: effect of blood exchange on tumour antibody uptake.
Desrues B; Quinquenel ML; Toujas L; Delaval P; Dazord L
Nucl Med Biol; 1995 Jul; 22(5):569-72. PubMed ID: 7581165
[TBL] [Abstract][Full Text] [Related]
12. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
[TBL] [Abstract][Full Text] [Related]
13. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies.
Behr TM; Béhé M; Löhr M; Sgouros G; Angerstein C; Wehrmann E; Nebendahl K; Becker W
Eur J Nucl Med; 2000 Jul; 27(7):753-65. PubMed ID: 10952487
[TBL] [Abstract][Full Text] [Related]
15. In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.
Schneider DW; Heitner T; Alicke B; Light DR; McLean K; Satozawa N; Parry G; Yoo J; Lewis JS; Parry R
J Nucl Med; 2009 Mar; 50(3):435-43. PubMed ID: 19223400
[TBL] [Abstract][Full Text] [Related]
16. Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice.
Kamath AV; Yip V; Gupta P; Boswell CA; Bumbaca D; Haughney P; Castro J; Tsai SP; Pacheco G; Ross S; Yan M; Damico-Beyer LA; Khawli L; Shen BQ
MAbs; 2014; 6(6):1631-7. PubMed ID: 25484068
[TBL] [Abstract][Full Text] [Related]
17. Effect of unlabelled monoclonal antibodies on the biodistribution of 111In-labelled anti-prostate-specific acid phosphatase monoclonal antibodies in the mouse model.
Peräalä-Heape M; Vihko P; Vihko R
Anticancer Res; 1991; 11(3):1327-31. PubMed ID: 1888168
[TBL] [Abstract][Full Text] [Related]
18. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
[TBL] [Abstract][Full Text] [Related]
19. Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
Mirallié E; Saï-Maurel C; Faivre-Chauvet A; Regenet N; Chang CH; Goldenberg DM; Chatal JF; Barbet J; Thedrez P
Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):901-9. PubMed ID: 15864584
[TBL] [Abstract][Full Text] [Related]
20. The effect of circulating antigen and radiolabel stability on the biodistribution of an indium labelled antibody.
Davidson BR; Babich J; Young H; Waddington W; Clarke G; Short M; Boulos P; Styles J; Dean C
Br J Cancer; 1991 Nov; 64(5):850-6. PubMed ID: 1931605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
